The startup develops decision support software that analyzes genetic data against a comprehensive database of clinical trials, expert insights, and patient outcomes. This technology enables oncologists to prescribe personalized treatment plans based on the unique molecular profiles of cancer patients, improving survival rates and treatment efficacy.
Funding
$3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Oncologists face the challenge of sifting through vast amounts of genomic data, clinical trials, and drug information to determine the most effective treatment plan for cancer patients. This process is time-consuming and requires specialized expertise to interpret complex molecular profiles and identify relevant therapeutic options. The lack of efficient tools for personalized medicine can lead to suboptimal treatment decisions and reduced patient outcomes.
Solution
CureMatch offers a decision support system that analyzes a patient's unique molecular tumor profile against a comprehensive database of FDA-approved drugs, clinical trials, and expert insights. The platform employs proprietary algorithms to rank and score combination drug therapies, providing oncologists with actionable intelligence to personalize cancer treatment. By considering the entire cancer-driving molecular profile, CureMatch helps clinicians identify optimal treatment strategies, even when standard therapies have failed or clinical trials are unavailable. The system integrates proteomic and genomic data to provide a comprehensive understanding of the patient's cancer biology, leading to more informed and effective treatment decisions.
Target Audience
The primary target audience includes oncologists, cancer centers, NGS labs, and concierge medicine providers seeking to leverage precision medicine for personalized cancer treatment. The platform also caters to biopharmaceutical companies looking to optimize clinical trials and improve patient stratification.
Features
- Analysis of patient-specific molecular profiling tests, including Next-Generation Sequencing (NGS) data
- Ranking and scoring of combination drug therapies based on the patient's unique genomic results
- Integration of proteomic and transcriptomic biomarkers for a more comprehensive analysis
- Access to a database of FDA-approved drugs, clinical trials, and expert insights
- Clinical Trial Intelligence (CTI) to optimize, rescue, and plan new clinical trials in oncology
- Identification of molecular biomarkers that can influence therapy success or failure
- Generation of clear, accessible reports with ranked combination drug therapies
- CPT Code 0794T for therapy matching and scoring service reimbursement